D J Dries1. 1. Department of Surgery, Loyola University Medical Center, Maywood, IL 60153, USA.
Abstract
OBJECTIVE: The efficacy of interferon gamma therapy in reducing infection and improving outcome from infection in patients sustaining major injury was examined. DESIGN: Randomized double-blind placebo control trial SETTING:Nine level one university affiliated trauma centers in the United States. PATIENTS AND PARTICIPANTS: Four hundred sixteen patients with injury severity score (ISS) > or = 25 or ISS > or = 20 with evidence of wound contamination. INTERVENTION: Recombinant human interferon gamma 100 ug or placebo was given subcutaneously daily for up to 21 days in addition to standard antibiotic therapy. MEASUREMENTS AND RESULTS: Comparable rates of major and minor infections were observed. Among the patients treated with interferon gamma there were fewer deaths related to major infection regardless of type [7-(3%) vs 18-(9%)]. The results, however, were dominated by one center which had the highest enrollment, infection and death rates. CONCLUSIONS: Further studies are warranted to investigate the role of interferon gamma therapy in improving outcome with major infection.
RCT Entities:
OBJECTIVE: The efficacy of interferon gamma therapy in reducing infection and improving outcome from infection in patients sustaining major injury was examined. DESIGN: Randomized double-blind placebo control trial SETTING: Nine level one university affiliated trauma centers in the United States. PATIENTS AND PARTICIPANTS: Four hundred sixteen patients with injury severity score (ISS) > or = 25 or ISS > or = 20 with evidence of wound contamination. INTERVENTION: Recombinant humaninterferon gamma 100 ug or placebo was given subcutaneously daily for up to 21 days in addition to standard antibiotic therapy. MEASUREMENTS AND RESULTS: Comparable rates of major and minor infections were observed. Among the patients treated with interferon gamma there were fewer deaths related to major infection regardless of type [7-(3%) vs 18-(9%)]. The results, however, were dominated by one center which had the highest enrollment, infection and death rates. CONCLUSIONS: Further studies are warranted to investigate the role of interferon gamma therapy in improving outcome with major infection.
Authors: D J Dries; G J Jurkovich; R V Maier; T P Clemmer; S N Struve; J A Weigelt; G G Stanford; D L Herr; H R Champion; F R Lewis Journal: Arch Surg Date: 1994-10
Authors: Christopher S Davis; Scott E Janus; Michael J Mosier; Stewart R Carter; Jeffrey T Gibbs; Luis Ramirez; Richard L Gamelli; Elizabeth J Kovacs Journal: Ann Surg Date: 2013-06 Impact factor: 12.969
Authors: Christopher S Davis; Joslyn M Albright; Stewart R Carter; Luis Ramirez; Hajwa Kim; Richard L Gamelli; Elizabeth J Kovacs Journal: J Burn Care Res Date: 2012 Jan-Feb Impact factor: 1.845
Authors: Richard S Hotchkiss; Lyle L Moldawer; Steven M Opal; Konrad Reinhart; Isaiah R Turnbull; Jean-Louis Vincent Journal: Nat Rev Dis Primers Date: 2016-06-30 Impact factor: 52.329
Authors: Patricia A Manderscheid; Ryan P Bodkin; Bruce A Davidson; Erik Jensen; Thomas A Russo; Paul R Knight Journal: Clin Diagn Lab Immunol Date: 2004-07